Slide Freedom to breathe

Axpira is a bronchodilator with Swiss short-acting beta-2 agonist particulate technology to mitigate asthmatic symptoms1, administered by inhalation. It can also be used for prophylaxis and treatment of bronchial asthma, bronchospasm associated with bronchitis and emphysema. It is CE 0344 certified in compliance with European regulation

Slide

An adequate inhalation technique should be used to ensure synchronization between the atomization of the drug and the aspiration, thus ensuring an optimal delivery of Axpira to the lungs.
It is contraindicated in patients with hypersensitivity to the drug, treatment of abortion, premature labor or first trimester of pregnancy. It should be used with caution in patients with hypertension, heart failure or thyrotoxicosis

Benefits

Provides relief over a three-hour perio

Mitigates asthmatic symptoms

Presentation

AXPIRA HFA 100 SALBUTAMOL

Bibliographic references:

  1. Erdinç M. (2011). Beta-2 agonist discussions in asthma and a review of current data. Tuberkuloz ve toraks59(2), 205–212.

Information:

Phone: + 601  616  0255

info@avalon.com.co

About Avalon

Website Map